Aclaris Therapeutics vs Apollomics
Aclaris Therapeutics and Apollomics are similar in size: $7.8m and $8.5m of revenue in their latest fiscal years. Apollomics kept more of each dollar of sales as profit: a net margin of -128.7% against -829.6%.
| Latest fiscal year | Aclaris TherapeuticsACRS, 2025 | ApollomicsAPLM, 2025 |
|---|---|---|
| Revenue | $7.8m | $8.5m |
| Revenue growth | -58.2% | — |
| Net income | −$64.9m | −$10.9m |
| Operating margin | -975.9% | — |
| Net margin | -829.6% | -128.7% |
| Return on equity | -50.2% | — |
| Free cash flow | −$47.2m | −$10.4m |
| Cash | $20.0m | $3.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 73 | — |
| Market value | $515m | $30.1m |
| Price vs our value range | — | — |
| Moat score | 14 (Weak) | — |
| Insider trades, 12 months | 0 buys, 1 sales | 5 buys, 0 sales |